UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000049727
Receipt number R000056642
Scientific Title Xocova tablets drug use-results survey
Date of disclosure of the study information 2022/12/08
Last modified on 2022/12/08 13:16:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Xocova tablets drug use-results survey

Acronym

Xocova tablets drug use-results survey

Scientific Title

Xocova tablets drug use-results survey

Scientific Title:Acronym

Xocova tablets drug use-results survey

Region

Japan


Condition

Condition

SARS-CoV-2 infection

Classification by specialty

Infectious disease

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To assess safety and clinical outcome of Xocova tablets under clinical practice.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Others

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

Safety
Incidence of adverse drug reactions

Key secondary outcomes

Clinical outcome
Time to resolution of COVID-19 symptoms in SARS-CoV-2 infected patients
The number and rate of hospitalization for COVID-19 or death from any cause through day 28


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

12 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

SARS-CoV-2 infected patient who has not been treated with Xocova tablets and provides an informed consent in written for data collection and analysis

Key exclusion criteria

NA

Target sample size

3000


Research contact person

Name of lead principal investigator

1st name Masako
Middle name
Last name Kaneto

Organization

Shionogi & Co., Ltd.

Division name

Pharmacovigilance Department

Zip code

541-0042

Address

3-13, Imabashi 3-Chome, Chuo-ku, Osaka 541-0042, Japan

TEL

+81-6-6209-6974

Email

masako.kaneto@shionogi.co.jp


Public contact

Name of contact person

1st name Satoru
Middle name
Last name Takashima

Organization

Shionogi & Co., Ltd.

Division name

Pharmacovigilance Department

Zip code

541-0042

Address

3-13, Imabashi 3-Chome, Chuo-ku, Osaka 541-0042, Japan

TEL

+81-6-6209-6929

Homepage URL


Email

satoru.takashima@shionogi.co.jp


Sponsor or person

Institute

Shionogi & Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Shionogi & Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

NA

Address

NA

Tel

NA

Email

NA


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 12 Month 08 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2022 Year 11 Month 22 Day

Date of IRB


Anticipated trial start date

2022 Year 12 Month 08 Day

Last follow-up date

2023 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

NA


Management information

Registered date

2022 Year 12 Month 08 Day

Last modified on

2022 Year 12 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056642


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name